Most prolactin-secreting pituitary adenomas demonstrate slow growth and are effectively
managed with medical/surgical therapy. Rarely, these tumors can behave aggressively with …

Context Temozolomide (TMZ) is endorsed as the treatment of choice in aggressive or
malignant pituitary adenomas. Objective Herein we describe a case of an aggressive …

Purpose Aggressive prolactinomas are defined as radiologically invasive tumors which
cannot be cured by surgery, and that have an unusually rapid rate of tumor growth despite …

Background Temozolomide is an oral alkylating agent with schedule-dependent antitumor
activity against high-grade malignancies including high-grade glioma. Increasingly, reports …

Dopamine agonists (DAs, especially cabergoline) are recommended as first-line treatment
in patients with prolactin-secreting pituitary adenomas, to reduce hormone secretion and …

Abstract Pituitary tumors represent 10–15% of all intracranial tumors; of these, prolactinomas
account for 40–50% of cases. Prolactinomas usually respond well to dopamine agonists …

Background The majority of prolactin-secreting pituitary macroadenomas are effectively
managed with dopamine-agonist therapy alone. Although surgical resection and …

Objective Invasive, medically refractory, and multiply recurrent pituitary adenomas pose a
rare, but nevertheless significant, challenge for conventional management modalities …

Administration of temozolomide to a 46-year-old man with an invasive aggressive prolactin
(PRL)–secreting pituitary neoplasm resulted in improvement of the clinical condition and …

Prolactinomas are common tumors of the anterior pituitary gland. While conventional
therapies, including dopamine agonists, transsphenoidal surgery and radiotherapy, are …